Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce its fourth quarter and full year 2020 financial results on February 25, 2021. A conference call will be held at 8:00 a.m. ET to discuss these results and provide a business update. Shareholders can use dial-in numbers 866-300-4091 (domestic) or 703-736-7433 (international) with conference ID 5865513. Kala is known for its innovative therapies for eye diseases, including EYSUVIS™ and INVELTYS™, and has ongoing pre-clinical development programs targeting key medical needs.

Positive

• Upcoming financial results announcement, potentially indicating growth or operational updates.
• Conference call arranged for detailed insights, enhancing investor communication.

Negative

• None.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 5865513. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY^® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS^® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005128/en/

FAQ

When will Kala Pharmaceuticals report its Q4 2020 financial results?

Kala Pharmaceuticals will report its fourth quarter 2020 financial results on February 25, 2021.

What time is the conference call for Kala Pharmaceuticals' financial results?

The conference call for Kala's financial results will be held at 8:00 a.m. ET on February 25, 2021.

Where can I access the live webcast of Kala Pharmaceuticals' conference call?

The live webcast can be accessed on the 'Events' section of the Kala Pharmaceuticals website.

What are the main products of Kala Pharmaceuticals?

Kala's main products include EYSUVIS™ for dry eye disease and INVELTYS™ for post-operative inflammation.